JP2021104048A5 - - Google Patents

Download PDF

Info

Publication number
JP2021104048A5
JP2021104048A5 JP2021063957A JP2021063957A JP2021104048A5 JP 2021104048 A5 JP2021104048 A5 JP 2021104048A5 JP 2021063957 A JP2021063957 A JP 2021063957A JP 2021063957 A JP2021063957 A JP 2021063957A JP 2021104048 A5 JP2021104048 A5 JP 2021104048A5
Authority
JP
Japan
Prior art keywords
composition
mil
bone marrow
mils
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021063957A
Other languages
English (en)
Japanese (ja)
Other versions
JP7197213B2 (ja
JP2021104048A (ja
Filing date
Publication date
Priority claimed from JP2017512293A external-priority patent/JP6865160B2/ja
Application filed filed Critical
Publication of JP2021104048A publication Critical patent/JP2021104048A/ja
Publication of JP2021104048A5 publication Critical patent/JP2021104048A5/ja
Application granted granted Critical
Publication of JP7197213B2 publication Critical patent/JP7197213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021063957A 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化 Active JP7197213B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045782P 2014-09-04 2014-09-04
US62/045,782 2014-09-04
US201562186040P 2015-06-29 2015-06-29
US62/186,040 2015-06-29
JP2017512293A JP6865160B2 (ja) 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017512293A Division JP6865160B2 (ja) 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Publications (3)

Publication Number Publication Date
JP2021104048A JP2021104048A (ja) 2021-07-26
JP2021104048A5 true JP2021104048A5 (https=) 2021-11-18
JP7197213B2 JP7197213B2 (ja) 2022-12-27

Family

ID=55440392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512293A Expired - Fee Related JP6865160B2 (ja) 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化
JP2021063957A Active JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017512293A Expired - Fee Related JP6865160B2 (ja) 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Country Status (13)

Country Link
US (7) US9687510B2 (https=)
EP (2) EP3922254A1 (https=)
JP (2) JP6865160B2 (https=)
KR (1) KR20170067751A (https=)
CN (1) CN107109364A (https=)
AU (2) AU2015311761B2 (https=)
CA (1) CA2959994C (https=)
DK (1) DK3188740T3 (https=)
ES (1) ES2877108T3 (https=)
IL (2) IL250746B (https=)
MX (1) MX391017B (https=)
PT (1) PT3188740T (https=)
WO (1) WO2016037054A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
US9687510B2 (en) * 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
CA2991040A1 (en) * 2015-06-29 2017-01-05 The Johns Hopkins University Immune checkpoint chimeric receptors therapy
EP3320087A4 (en) * 2015-07-08 2019-01-23 The Johns Hopkins University BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
JP2020512284A (ja) * 2016-12-22 2020-04-23 ウィンドミル セラピューティクス インコーポレイテッド 免疫系調節組成物および方法
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
EP3735256A4 (en) 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2022507113A (ja) * 2018-11-05 2022-01-18 ウィンドミル セラピューティクス インコーポレイテッド クローン性の増大した骨髄浸潤リンパ球およびそれらの使用
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
WO2020198031A1 (en) * 2019-03-22 2020-10-01 Windmil Therapeutics Inc. Lung cancer specific marrow infiltrating lymphocytes and uses thereof
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
WO2025160242A1 (en) * 2024-01-23 2025-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of generating tils from cerebro spinal fluid for leptomeningeal disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3243600A (en) 1999-02-23 2000-09-14 Kathleen S. Carswell Improved method of culturing t cells
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
WO2008147482A2 (en) * 2007-02-13 2008-12-04 Northeastern University Methods and compositions for improving immune responses
WO2010062742A2 (en) * 2008-11-03 2010-06-03 The Johns Hopkins University Methods for freparation and use of marrow infiltrating lymphocytes (mils)
WO2014085437A2 (en) * 2012-11-27 2014-06-05 The Johns Hopkins University Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
BR112014007947A2 (pt) 2011-10-03 2017-04-18 Univ Los Andes método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
WO2013109759A1 (en) * 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
JP2014090678A (ja) * 2012-11-01 2014-05-19 Ito En Ltd 容器詰野菜汁及び/又は果汁含有飲料及びその製造方法、並びに容器詰野菜汁及び/又は果汁含有飲料の呈味劣化防止方法
US9687510B2 (en) 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2020512284A (ja) * 2016-12-22 2020-04-23 ウィンドミル セラピューティクス インコーポレイテッド 免疫系調節組成物および方法
EP3735256A4 (en) * 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY

Similar Documents

Publication Publication Date Title
JP2021104048A5 (https=)
US20230000919A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2017527286A5 (https=)
RU2015138483A (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
JP2016509840A5 (https=)
JP3619853B2 (ja) ナチュラルキラー細胞の増殖方法
CN109609451B (zh) 体外快速扩增肾癌的肿瘤浸润淋巴细胞的方法
JP2021502816A5 (https=)
Pidruchna et al. Dynamics of indicators of cellular immunity in conditions of acute generalized peritonitis in rats
CN108690829B (zh) 一种高效扩增nk细胞的方法
Chen-Woan et al. Isolation and characterization of protective T cells induced by Listeria monocytogenes
Metelo et al. Allogeneic anti-Bcma CAR-T cells show tumour specific killing against primary multiple myeloma cells from different genomic sub-groups
CN102596209A (zh) 含有短暂性存活ctl的医药品组合物
JPS6011889B2 (ja) 継代可能なリンホカイン産生ヒトt細胞融合株及びその取得方法
JPWO2019183455A5 (https=)
CN113293130A (zh) 一种肿瘤特异性t细胞的培养方法
JPWO2022204523A5 (https=)
HK40064965A (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
WO2024243679A1 (en) Innate lymphoid cells for cell therapy and biomarkers therefor
CN116515751A (zh) 一种自体特异性t细胞的体外扩增方法
WO2025196582A1 (en) A method for preparing chimeric antigen receptor (car) expressing cells
CN121780433A (zh) 一种调节性t细胞的体外扩增培养方法及培养基
CN112251466A (zh) 一种低病毒用量的car-t制备方法
HK1240085A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
NZ758201B2 (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy